Currently, there is no consensus as to the optimal method for measuring tumor length or percentage of cancer on a core when there are 2 or more foci of prostate cancer in a single core separated by benign intervening stroma. One option is to measure discontinuous foci of cancer as if they were 1 single continuous focus. The other option is to add the measurements of the individual separate foci of cancer, ignoring the extent of the intervening benign prostate tissue. The surgical pathology database at The Johns Hopkins Hospital was searched for outside consult cases of prostate needle biopsies reviewed between 2005 and 2010 when the patient came to our institution for radical prostatectomy (RP). Cases were restricted to those with biopsy Gleason score 6 in which there was at least 15% discordance between the outside and our institution in terms of the reported highest percentage of cancer per core per case. One hundred and nine patients were identified fulfiling our inclusion criteria. Seventy-nine showed the same Gleason score in the RP, and 30 had an upgrade to Gleason Z7. Including all cases (scores 6, 7, and 8 at RP), there was no significant association between the maximum percentage of cancer per core with organconfined disease or risk of positive surgical margins, regardless if the cores were measured at Hopkins or at the outside institutions. For cases with no upgrade at RP, the differences between the maximum percentage of cancer per core per case recorded at Hopkins and the outside institutions ranged from 15% to 80%, in which the mean and median differences were 35% and 30%, respectively. The maximum percentages of tumor involvement on a core per case given at our institution more strongly correlated with the presence of organ-confined disease (P = 0.004) compared with the percentages given at the outside institutions (P = 0.027). Surgical margin positivity was also associated with the maximum percentages of tumor involvement per core given at our institution (P = 0.004), whereas the outside percentages were not significant predictors of margin status (P = 0.2). In a multivariable analysis, maximum percentage of cancer per core per case measured at Hopkins which includes intervening benign prostate tissue in the measurement was also more predictive of stage and margins than ignoring intervening benign tissue. In summary, our study demonstrated that for prostate cancer in which the needle biopsy grade is representative of the entire tumor, quantifying cancer extent on biopsy by measuring discontinuous cancer on biopsy from one end to the other as opposed to "collapsing" the cancer by subtracting out the intervening benign prostate tissue correlates better with organ-confined disease and risk of positive margins.
Abstract: Currently, there is no consensus as to the optimal method for measuring tumor length or percentage of cancer on a core when there are 2 or more foci of prostate cancer in a single core separated by benign intervening stroma. One option is to measure discontinuous foci of cancer as if they were 1 single continuous focus. The other option is to add the measurements of the individual separate foci of cancer, ignoring the extent of the intervening benign prostate tissue. The surgical pathology database at The Johns Hopkins Hospital was searched for outside consult cases of prostate needle biopsies reviewed between 2005 and 2010 when the patient came to our institution for radical prostatectomy (RP). Cases were restricted to those with biopsy Gleason score 6 in which there was at least 15% discordance between the outside and our institution in terms of the reported highest percentage of cancer per core per case. One hundred and nine patients were identified fulfiling our inclusion criteria. Seventy-nine showed the same Gleason score in the RP, and 30 had an upgrade to Gleason Z7. Including all cases (scores 6, 7, and 8 at RP), there was no significant association between the maximum percentage of cancer per core with organconfined disease or risk of positive surgical margins, regardless if the cores were measured at Hopkins or at the outside institutions. For cases with no upgrade at RP, the differences between the maximum percentage of cancer per core per case recorded at Hopkins and the outside institutions ranged from 15% to 80%, in which the mean and median differences were 35% and 30%, respectively. The maximum percentages of tumor involvement on a core per case given at our institution more strongly correlated with the presence of organ-confined disease (P = 0.004) compared with the percentages given at the outside institutions (P = 0.027). Surgical margin positivity was also associated with the maximum percentages of tumor involvement per core given at our institution (P = 0.004), whereas the outside percentages were not significant predictors of margin status (P = 0.2). In a multivariable analysis, maximum percentage of cancer per core per case measured at Hopkins which includes intervening benign prostate tissue in the measurement was also more predictive of stage and margins than ignoring intervening benign tissue. In summary, our study demonstrated that for prostate cancer in which the needle biopsy grade is representative of the entire tumor, quantifying cancer extent on biopsy by measuring discontinuous cancer on biopsy from one end to the other as opposed to "collapsing" the cancer by subtracting out the intervening benign prostate tissue correlates better with organ-confined disease and risk of positive margins. O ne of the pathologist's roles in the assessment of prostate needle biopsies containing adenocarcinoma is to quantify the extent of cancer. In addition to noting the number of positive cores, an additional more detailed method of measuring the cancer is expected. Several different tumor measurements have been proposed, but no clear advantage of one method over the other has been found. 1, 6 One of the scenarios in which the extent of cancer drives clinical management is in patients under consideration and being followed for active surveillance. Although prostate-specific antigen (PSA)-based screening strategy has reduced prostate cancer-related deaths by 20%, it has lead to the overtreatment of prostate cancer, particularly when detected at its early stages. 10, 12 In an attempt to decrease overtreatment, active surveillance as an option was introduced into the clinical arena, and guidelines for the management of clinically localized prostate cancer were proposed. 13 One of the eligibility criteria commonly applied in the selection of candidates for active surveillance requires the identification of no >50% of prostate cancer involving any needle biopsy core. 8 Although this criterion would seem to most clinicians as straightforward, at present there is no consensus as to the optimal method for measuring tumor length or percentage on a core, especially when there are 2 or more foci of prostate cancer in a single core separated by benign intervening stroma. At our institution, we measure discontinuous foci of prostate cancer in needle biopsies as if they were 1 single continuous focus. In contrast, the majority of cases sent in from outside institutions, in which we review the case before treatment is initiated at our institution, mentally collapse all the separate cancer foci, add up the separate percentages of tumor involvement, and ignore the percentage of intervening benign prostate tissue. In this study, we aim to compare both approaches in terms of their performances in predicting organconfined disease and risk of positive surgical margins in corresponding radical prostatectomy (RP) specimens.
MATERIALS AND METHODS
The surgical pathology database at The Johns Hopkins Hospital was searched for outside consult cases of prostate needle biopsies reviewed between 2005 and 2010 when the patient came to our institution for RP. The year 2005 was used as the initiating time, as it coincides with the publication of the updated Gleason grading system. 6 Only cases in which the outside report included separate percentages of involvement for each core were included to directly compare with the percentage recorded at our institution. The maximum percentage of cancer per core in a given case was selected as the percentage of cancer for that case. All RP specimens were serially sectioned and entirely submitted for histologic examination. Information on the corresponding RP Gleason score, presence of extraprostatic extension, surgical margins, PSA, and clinical stage was retrieved from the Brady Urological RP Database and The Johns Hopkins Pathology Data System.
Cases were restricted to those with biopsy Gleason score 6, in which there was at least a 15% discordance between the outside and our institution in terms of the reported highest percentage of cancer per core per case ( Fig. 1 ). Gleason score 6 cases were included as that is one of the criteria for inclusion within most active surveillance programs, including ours. Requiring Z15% discrepancy between the outside and Hopkins assessment of cancer percentage selected for cases which could be ascribed to differing methodology of how to measure discontinuous foci of cancer. In contrast, more minor differences could be attributable to subjective differences in estimating cancer extent using the same methodology. Two cases with organ-confined disease at RP were randomly selected to serve as controls for each RP with extraprostatic extension.
One hundred and nine patients were identified fulfilling our inclusion criteria. Seventy-nine patients showed the same Gleason score in the RP, 28 had an upgrade to Gleason score 7, and 2 had an upgrade to Gleason score 8. Four patients had evidence of seminal vesicle involvement, and only 1 patient had lymph node involvement. Information on clinical stage was not available for 2 patients. Analyses were initially carried out for all cases (RP Gleason scores 6 to 8). Cases with no Gleason upgrade (RP Gleason score 6 only) were then analyzed separately.
Statistical Analysis
Mean PSA and percentages of tumor involvement were compared using the Student t test. The w 2 test was used for categorical variables. Backward stepwise logistic regression models based on likelihood ratios were used to evaluate the impact of preoperative parameters (percentage on needle biopsy, PSA, and clinical stage) for predicting organ-confined disease and positivity of surgical margins. A 2-tailed P<0.05 was required for statistical significance. Findings were analyzed using the STATA version 11 (StataCorp Inc., College Station, TX) software package.
RESULTS

All Cases (Including Those With Upgrade at RP)
Including all cases (scores 6, 7, and 8 at RP), there was no significant association between the maximum percentage of cancer, regardless if measured at Hopkins or at the outside institutions, with organ-confined disease or risk of positive surgical margins (P<0.05).
Cases With no Upgrade at RP
The mean age of the patients was 57.4 years (range, 43 to 70 y). Organ-confined disease was identified in 56 patients, whereas in 23 cases it was nonorgan confined. Surgical margins were positive in 14 cases. The mean serum PSA level was 5.3 ng/mL. The maximum percentages of cancer per core given at Hopkins and the outside institutions are summarized in Table 1 . The differences FIGURE 1. A, Several small foci of adenocarcinoma (arrows) discontinuously involve 80% of the length of the core (measured at Johns Hopkins), compared with 7% core involvement (excluding benign tissue) recorded at the outside institution. B, Different case from Figure 1A with triple stain consisting of p63 and high-molecular weight cytokeratin (brown chromogen) and racemase (red chromogen) showing 3 discontinuous foci of adenocarcinoma with lack of basal cells and positivity for racemase (arrows). The tumor discontinuously involved 50% of the core length (measured at Johns Hopkins), compared with 15% when intervening benign tissue was discounted (measured at outside institution).
between the maximum percentage of cancer per core per case recorded at Hopkins and the outside institutions ranged from 15% to 80%, in which the mean and median differences were 35% and 30%, respectively (Fig. 2) .
The mean serum PSA levels were significantly different between the organ-confined and nonorganconfined groups (P = 0.017), and also between the cases with positive and negative surgical margins (P = 0.013). No significant difference in clinical stage were found between the organ-confined and nonorgan-confined groups (P = 0.85), and between cases with positive and negative surgical margins (P = 0.75).
PSA levels and percentages of tumor involvement, but not clinical stage, were significantly associated with the presence of organ-confined disease ( Table 2 ). The maximum percentages of tumor involvement on a core per case given at our institution more strongly correlated with the presence of organ-confined disease (P = 0.004) compared with the percentages given at the outside institutions (P = 0.027). Surgical margin positivity was associated with serum PSA levels and the maximum percentages of tumor involvement per core given at our institution, whereas the outside percentages were not significant predictors of margin status (Table 3) .
By multivariate analysis, only the maximum percentage of cancer per core on needle biopsy remained a significant predictor of organ confined disease, with the percentage measured discontinuously a stronger predictor of organ confined disease (P = 0.007) compared with the maximum percentage recorded at the outside institutions (P = 0.033). In multivariate analysis, predicting margin positivity percentage on needle biopsy remained a significant predictor only when measuring the percentage discontinuously (P = 0.009), whereas the outside recorded percentages lacked significance for predicting margin status (P>0.05).
DISCUSSION
The most common methods of recording the extent of cancer in prostate needle biopsy core specimen include the reporting of: (1) number of positive cores; (2) fraction of positive cores (number of positive cores/total cores); (3) total millimeters of cancer among all cores; (4) total percentage of cancer in the entire specimen; (5) millimeters of cancer per core; and (6) percentage of cancer per core. 1 When multiple cores are submitted in a single jar by the urologist and processed by the pathologist in a single cassette, some limitations to the above methods exist. In this situation, many pathologists give the overall percentage of cancer for the entire slide as opposed to the percentage for each individual core. At our institution, we attempt to give the percentage of cancer per core for each individual positive core, regardless of how many cores are on a given slide. In addition, if there are multiple fragmented small cores containing cancer, an accurate assessment of percentage of cancer per core cannot be determined, and only an overall percentage of cancer per fragmented specimen can be noted. In this latter scenario, one cannot even determine with certainty the number of positive cores.
In addition to different methods of quantifying cancer on needle biopsy specimens, there is 1 situation in which there are significant differences as to how cancer is quantified within a given method. This difference occurs when cancer discontinuously involves a core with varying amounts of intervening benign prostate tissue. The options are: (1) measure discontinuous foci of prostate cancer in needle biopsies as if they were 1 single continuous focus; and (2) mentally collapse all the separate cancer foci, add up the separate percentages of tumor involvement, and ignore the percentage of intervening benign prostate tissue. The same choices would apply if one was measuring the cancer in millimeters. On the basis of a survey of pathologists, both these methods are almost equally commonly used. 5 At our institution, we utilize the first method that is recording the percentage of cancer from where the cancer begins and ends on the core, as if there was no intervening benign prostate tissue. Calculating the percentage of each core involved by cancer is based on a visual estimate of the length of the cancer involvement divided by the length of the core. Our rationale for doing so is that these discontinuous foci are undoubtedly in the overwhelming number of cases the same cancer going in and out of the plane of the section in contrast to multifocal cancer. Thus, measuring the cancer from where it starts to where it ends on the core would give the minimal diameter of cancer in the prostate, and might better reflect the actual tumor volume. To explain potential discrepancies between our measurement and those institutions utilizing the second method described above, we report these cases using terminology such as the following: "Small foci of adenocarcinoma of the prostate, Gleason score 3+3 = 6, discontinuously involving 60% of the length of the core." As described above, if the core is fragmented we then report only the overall percentage of cancer per tissue on the slide.
There has been almost no data attempting to determine which methods of measuring discontinuous foci are superior to predict pathologic outcome at RP. In the only earlier study addressing the issue, the researchers found no prognostic difference among various methods used to report tumor volume when discontinuous foci were encountered. 1 However, our study design differs from theirs in at least 1 critical aspect. Most of the cases reported by Brimo et al 1 had cases in which the intervening stroma between cancer was r5 mm. Including a majority of cases in which the extent of cancer was the same, whether measured by accounting for or ignoring intervening benign prostate tissue, would potentially obscure any prognostic differences for cases with greater differences between the 2 methods. In our study, cases were selected in which the differences between Hopkins and the outside institution reported percentages were more divergent so as to specifically address this issue. Patients in the study by Brimo et al 1 also had more advanced cancer, with 34% having high-stage disease (pT3 or PN1) and a mean Gleason score of 6.7. As noted in our study, the advantage of measuring discontinuous foci of cancer by including intervening benign prostate tissue was lost in cases with upgrading at RP.
This study demonstrated that in cases in which there is Gleason score 6 on needle biopsy and no upgrading at RP, the maximum percentage of cancer per core measured by including intervening benign tissue correlates with organ-confined disease and risk of positive margins better than measuring cancer in which the benign intervening tissue is not factored in. In cases in which there is upgrading at RP to Gleason score Z7, this predictive correlation is lost. At our institution, men typically undergo RP within 3 months of their needle biopsy diagnosis of cancer. Cancers that are upgraded at RP compared with their needle biopsy grade reflect under sampled tumor rather than true tumor progression. 4 The likely explanation for why the extent of cancer on biopsy, regardless of the technique utilized, did not correlate with RP stage or margin status when there was upgrading at RP is that the cancer on needle biopsy did not accurately reflect the entire cancer not only in terms of its grade, but also in its extent. As the cancer on needle biopsy was not representative of the most aggressive component of the RP tumor, it is not surprising that the extent of cancer on biopsy was not predictive of pathologic stage or margin status. From the standpoint of understanding the biology of prostate cancer, when the needle cancer on needle biopsy is representative of the RP cancer, measuring discontinuous foci of cancer on needle biopsy by factoring in rather than excluding intervening benign prostate tissue best predicts pathologic stage and margin status.
A critical situation in which prostate needle biopsy tumor volume is used clinically is in deciding which men are candidates for active surveillance. One of the most commonly used criteria for selecting men for active surveillance is Gleason score 6 on biopsy, <50% maximum percentage of cancer per core, PSA density (PSA/gland weight) <0.15, and no more than 2 positive cores. These criteria, validated in retrospective and prospective studies, correlate with a decreased risk of upgrading at RP. 3, 7 Numerous studies have demonstrated that lower serum PSA levels are associated with a decreased risk of upgrading at RP. 9 In addition, the larger the prostate, the lower the risk of upgrading at RP. 14 Consequently, lower PSA density (PSA/gland volume) is even more predictive of a lower risk of upgrading compared with serum PSA alone. 11 Fewer positive cores in most studies also predict a lower risk of upgrading at RP in men with Gleason score 6 on biopsy. 2 Consequently, in men who are being considered for active surveillance where their favorable biopsy and clinical features predict for less upgrading, the percentage of the biopsy involved by cancer measured discontinuously is more likely to predict which cases with Gleason score 6 cancer on biopsy are organ confined. Similar data can be used for men being considered for radiotherapy, in which this information is critical in deciding whether brachytherapy, as monotherapy, is an option.
The retrospective nature of our study and the relatively small sample size are inherent limitations in our study. As slides received in consultation are routinely returned to their original institution after being reviewed, we could not independently rereview the cases. Moreover, many cases were rendered nonevaluable for various reasons: (1) multiple cores on a single slide were given at the outside institution an overall percentage as opposed to percentage per core; (2) fragmented cores precluded an accurate assessment of percentage of core involvement;
(3) outside recording of cancer used different methods than percentage of cancer per core; (4) cases with very small or extensive cancer in which, regardless of the technique used, the measurement was the same; and (5) other cases in which the percentages between Hopkins and the outside institution was <15%. In addition, there is a third method that we could not assess in this retrospective study in which some centers include the benign stroma in the calculation if the tumor foci are <1 low-power field apart (5 to 5.5 mm). If farther apart, they consider these as 2 potentially separate foci and do not include the benign stroma. We are initiating a prospective study whereby consult cases with discontinuous involvement would be evaluated by the same pathologist using both our method and the method in which intervening benign tissue is not accounted for and then correlated with RP findings. We will only select cases that would be candidates for active surveillance as this is the population where currently the maximum percentage of the core involved by cancer is critical in patient management.
In this study, a comparison between other methods of measuring cancer such as millimeters of cancer was not evaluated, as at our institution we only report the percentage of core involved by cancer, as this is the measurement criteria used in selecting men for active surveillance. However, it is likely that the same situation would apply if one used millimeters of cancer. Based on our study, measuring the focus of cancer from its beginning to end including the length of intervening benign tissue would likely be more predictive than summing the lengths of individual foci of cancer.
In summary, our study demonstrated that for prostate cancer in which the needle biopsy grade is representative of the entire tumor, the following holds true. Quantifying cancer extent on biopsy by measuring discontinuous cancer on biopsy from one end to the other as opposed to "collapsing" the cancer by subtracting out the intervening benign prostate tissue correlates better with organ confined disease and risk of positive margins. This study is the first to specifically address this issue and shows significant difference between these different methods for tumor quantification on needle biopsy. Further studies, designed prospectively and including a larger sample size, will be needed to confirm this finding.
